Eosinophilic Esophagitis (EoE) Clinical Trial
Official title:
Prostaglandin and Cannabinoid Receptors in the Development of Eosinophilic Esophagitis
The purpose of this study is to investigate prostaglandin and cannabinoid receptors and their endogenous ligands in eosinophilic esophagitis (EoE). A prostaglandin D2 receptor antagonist has been shown to improve disease symptoms suggesting a regulatory role for bioactive lipids in EoE. Prostaglandin D2 and E2, and endocannabinoids are lipid mediators that govern the functional and inflammatory behavior of immune cells critical for EoE development. The prostaglandin D2 and E2 receptor axis, and the components of the endocannabinoid may be involved in the pathogenesis of EoE.
Prostaglandin D2 and E2 receptors, and components of the endocannabinoid system (cannabinoid receptors and endocannabinoid-metabolizing enzymes) are examined in mucosal esophageal biopsies and blood leukocytes from EoE patients (acute and in remission), individuals with gastroesophageal reflux and from individuals with no esophageal disease. Expression of these components are compared between all cohorts by polymerase chain reaction, Western blots, flow cytometry and immunohistochemical methods. EoE disease activity is evaluated by determining a symptom score and the number of eosinophils per high-power field (hpf) in histologic sections of mucosal biopsies. Additionally, an Endoscopic Reference Score (EREFS) is used. Disease activity is correlated with cannabinoid/prostaglandin D2 and E2 receptor expression. Blood is collected and immediately processed for flow cytometric experiments. Prostaglandins and endocannabinoids are measured in plasma and esophageal mucosal biopsy samples of all cohorts by mass spectrometry. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04394351 -
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
|
Phase 3 | |
| Terminated |
NCT03245840 -
Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)
|
Phase 3 | |
| Completed |
NCT03581838 -
Eating With Eosinophilic Esophagitis (EoE)
|
||
| Completed |
NCT02778867 -
SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study
|
Phase 2/Phase 3 | |
| Completed |
NCT01642212 -
OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension
|
Phase 2 | |
| Completed |
NCT05485779 -
SAD, MAD and Food Effect Evaluation of Safety, Tolerability, and PK of AQ280 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT00762073 -
Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis
|
Phase 2 | |
| Terminated |
NCT02058537 -
Bethanechol for Eosinophilic Esophagitis
|
Phase 2 | |
| Completed |
NCT02605837 -
A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved
|
Phase 3 | |
| Completed |
NCT02320981 -
Mucosal Impedance in Pediatric Population
|
N/A | |
| Recruiting |
NCT06389994 -
Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy
|
||
| Completed |
NCT02736409 -
An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)
|
Phase 3 |